methyl 3-methyl-N-({[(1S,2S)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valinate | 1026200-26-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 3-methyl-N-({[(1S,2S)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valinate
• 英文别名: methyl (2S)-3,3-dimethyl-2-[[(1S,2S)-2-pent-4-enylcyclopropyl]oxycarbonylamino]butanoate
• CAS: 1026200-26-9
• 化学式: C₁₆H₂₇NO₄
• 分子量: 297.395
• InChiKey: XICWIJTZJWEJFY-RWMBFGLXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  trimethyl{[(trans)-2-pent-4-en-1-ylcyclopropyl]oxy}silane 在 吡啶 、 4-二甲氨基吡啶 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 6.0h， 生成 methyl 3-methyl-N-({[(1R,2R)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valinate 、 methyl 3-methyl-N-({[(1S,2S)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valinate
  参考文献：
  名称：

  Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

  摘要：

  A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clinically relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.

  DOI：

  10.1021/ml300017p

文献信息

• Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors
  申请人：Harper Steven

  公开号：US20100029666A1

  公开（公告）日：2010-02-04

  The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.

  本发明涉及一种具有化学式(I)的大环化合物，以及其作为丙型肝炎病毒（HCV）NS3蛋白酶抑制剂的用途，用于治疗或预防HCV感染。
• HCV NS3 Protease Inhibitors
  申请人：Liverton Nigel J.

  公开号：US20100099695A1

  公开（公告）日：2010-04-22

  The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

  本发明涉及公式（I）的大环化合物，其可用作丙型肝炎病毒（HCV）NS3蛋白酶的抑制剂，它们的合成以及它们用于治疗或预防HCV感染的用途。
• Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitor
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2540349A1

  公开（公告）日：2013-01-02

  The present invention relates to a macrocyclic compound of formula (I) useful as an inhibitor of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections, in solid pharmaceutical compositions suitable for oral administration.

  本发明涉及一种式（I）的大环化合物，可作为丙型肝炎病毒（HCV）NS3蛋白酶的抑制剂，在适合口服的固体药物组合物中用于治疗或预防HCV感染。
• Combinations of a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitors with other HCV agents
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2540350A1

  公开（公告）日：2013-01-02

  The present invention relates to a macrocyclic compound of formula (I) useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections, in combination with other therapeutic agents.

  本发明涉及一种式（I）的大环化合物，可作为丙型肝炎病毒（HCV）NS3蛋白酶的抑制剂，与其他治疗剂联合使用，治疗或预防HCV感染。
• MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2310095B1

  公开（公告）日：2012-08-29